Andamertinib
Andamertinib is an investigational new drug that is being develop by Avistone Biotechnology Co., Ltd. for the treatment of non-small-cell lung cancer (NSCLC).
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Andamertinib is an investigational new drug that is being develop by Avistone Biotechnology Co., Ltd. for the treatment of non-small-cell lung cancer (NSCLC). It is an epidermal growth factor receptor (EGFR) antagonist. Andamertinib is an irreversible EGFR inhibitor designed to target EGFR with exon 20 insertion mutations.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374839493 under CC BY-SA 4.0; modifications have been made.